Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.

Oncotarget - 19 Jul 2016

Chong Dawn Q, Zhu Andrew X

Abstract excerpt

Cholangiocarcinoma (CCA) is a relatively rare malignancy that arises from the epithelial cells of the intrahepatic, perihilar and distal biliary tree. Intrahepatic CCA (ICC) represents the second most common primary liver cancer, after hepatocellular cancer. Two-thirds of the patients with ICC present with locally advanced or metastatic disease. Despite standard treatment with gemcitabine and cisplatin, prognosis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms
Share to Cholangiocarcinoma
Share to Gene Fusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Programmed Cell Death 1 Receptor

Share to Proto-Oncogene Mas

Share to Proto-Oncogene Proteins c-met

Share to Receptor, Fibroblast Growth Factor, Type 2

Share to Receptors, Vascular Endothelial Growth Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 27102149
DOI: 10.18632/oncotarget.8775
PMCID: PMC5216834

Genes

FGFR2
ROS1
BAP1
BRAF
BRCA1
EGFR
IDH1
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.PMID 27102149Read ↗

Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Molecular Subtypes and Precision Oncology in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Molecular biology of cholangiocarcinoma and its implications for targeted therapy in patient management.Semantic proximity Read ↗

Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.Semantic proximity Read ↗

Molecular Pathogenesis of Cholangiocarcinoma: Implications for Disease Classification and Therapy.Semantic proximity Read ↗

Charting co-mutation patterns associated with actionable drivers in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.Semantic proximity Read ↗

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Molecular Profile of Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Intrahepatic cholangiocarcinoma: current management and emerging therapies.Semantic proximity Read ↗

Genomic Landscape of Cholangiocarcinoma in India: Ethnic Variants and Implications for Targeted TherapySemantic proximity Read ↗

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.